Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims




Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.



Source link

About The Author

Scroll to Top